Pneumococcal disease remains a major cause of morbidity among older adults. This analysis estimated the number of invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (pCAP) cases that could be prevented among adults aged 65 years or older in Japan under the national immunization program if administered with either the 20-valent conjugate vaccine (PCV20) or the 21-valent conjugate vaccine (PCV21).
The analysis sought to combine observed serotype distribution and annual incidence data with reported vaccine efficacy and duration of protection in older adults to quantify preventable disease burden for each vaccine option.
The authors used two primary data sources: a nationwide surveillance study of adult IPD and a multicenter clinical study of pCAP. They monitored serotype distribution among pneumococcal isolates and tracked annual IPD incidence in adults.
The modeling incorporated reported vaccine efficacy estimates and assumed durations of protection for older adults; specific numeric values for efficacy and duration as applied in the model were not reported in the source summary. Preventable-case estimates were generated for the period 2023–2025 and applied to the target population aged ≥65 years. Analyses assumed a vaccination coverage of 40% in the eligible population.
Surveillance data showed that the mean annual incidence of adult IPD caused by all serotypes declined during the COVID-19 pandemic period but had partially rebounded by 2025. By 2025 the incidence in adults aged ≥65 years had recovered to 89% of the pre-pandemic level.
In the 2023–2025 interval, isolates with serotypes that are included in PCV20 but not in PCV21 (PCV20-non-PCV21 serotypes) represented 8.5% of adult IPD isolates in the ≥65 age group.
Using the surveillance and clinical data, and applying reported vaccine efficacy and duration assumptions, the authors estimated preventable cases at the current vaccination coverage of 40%:
Preventable IPD cases (reported as numbers per person per year in the source): 36 for PCV20 and 53 for PCV21.
Preventable pCAP cases: 2,821 for PCV20 and 4,765 for PCV21.
The analysis noted a marked difference in absolute numbers between IPD and pCAP: the estimated number of preventable pCAP cases was approximately 80–90 times higher than the estimated preventable IPD case count.
Across the modeled scenarios and the 2023–2025 serotype distribution, PCV21 could prevent approximately 1.5–1.7 times as many pneumococcal disease cases as PCV20 among adults aged ≥65 years in Japan. This reflects the additional serotype coverage provided by PCV21 relative to PCV20 under the observed serotype mix.
However, the authors emphasize a policy caveat: if the incidence of adult IPD caused by PCV20-non-PCV21 serotypes rises, the relative advantage of PCV21 could narrow and PCV20 might become the preferred option. Decision-making should therefore consider ongoing surveillance of serotype epidemiology.
The summary does not provide the detailed numerical vaccine efficacy inputs or the full model structure; those specifics were not reported in the source summary. The estimates therefore depend on the efficacy and duration assumptions cited by the authors, which were not detailed in the abstract-level text.
Ethical review: the study was reviewed and approved by the Medical Research Ethics Committee of JIHS, NIID (approval no. 707), and conducted in accordance with the Declaration of Helsinki. The authors declared no competing interests. Data will be made available upon reasonable request.
Clinicians and policymakers should interpret the relative prevention estimates in the context of local serotype dynamics, vaccine availability, programmatic considerations, and continuing surveillance for shifts in serotype-specific disease incidence.